GSC
CBIO

Ground Swell Capital’s Crescent Biopharma CBIO Stock Holding History

Ground Swell Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-332
Closed -$8.27K – 190
2024
Q4 		$8.27K Buy
+332
New +$9.05K 0.01% 137

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ground Swell Capital's CBIO Position: Q1 2025 in Review

Ground Swell Capital sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 332 shares — an estimated $8.27K sold.

Ground Swell Capital first reported a position in CBIO in Q4 2024 and held it in 1 quarter. The position peaked at $8.27K in Q4 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

  • Ground Swell Capital reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
  • Ground Swell Capital sold 332 Crescent Biopharma shares in Q1 2025, an estimated $8.27K.
  • Ground Swell Capital first reported a position in Crescent Biopharma in Q4 2024 and held it in 1 quarter.
  • Ground Swell Capital's Crescent Biopharma position peaked at $8.27K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on Ground Swell Capital's 13F filing for Q1 2025, filed 13 May 2025.